Advertisement


Silvia Formenti, MD, on Testing Radiation and Immune Checkpoint Blockade in Different Tumor Settings

AACR Virtual Annual Meeting 2020 II

Advertisement

Silvia Formenti, MD, of Weill Cornell Medical College, discusses her continuing work, and the promising results emerging, in combining radiotherapy with immunotherapy to boost abscopal response rates. This combination therapy extends the use of radiotherapy to promote antitumor T-cell responses for both local and metastatic disease (Session ED37).



Related Videos

Issues in Oncology
Leukemia

Alfonso Bencomo Álvarez, PhD, on ALL, AML, and CML: Survival for Hispanic Patients Living Near the US/Mexico Border

Alfonso Bencomo Álvarez, PhD, of Texas Tech University Health Sciences Center, discusses his retrospective study of the incidence and survival for patients with hematologic malignancies residing at the United States/Mexico border. The analysis showed that 10-year survival rates for Hispanic patients with ALL, AML, and CML were significantly lower for those who lived in El Paso than for those who lived elsewhere in Texas (Abstract 4343).

Lung Cancer
Immunotherapy

Nasser K. Altorki, MD, on Lung Cancer: Radiotherapy and Immune Checkpoint Blockade in the Neoadjuvant Setting

Nasser K. Altorki, MD, of Weill Cornell Medical College, discusses study findings that suggest neoadjuvant low-dose focal stereotactic body radiation plus immune checkpoint blockade (ICB) is safe and causes no surgical delays in early-stage lung cancer, and that major pathologic response rates are likely to be comparable to those with chemotherapy/ICB combinations (Session ED37).

Colorectal Cancer

Xavier Llor, MD, PhD, on Colorectal Cancer: Why Are More Younger People Being Affected?

Xavier Llor, MD, PhD, of Yale University School of Medicine, discusses the steep rise of early-onset colorectal cancer over the past 15 years, which cannot be explained by genetic predisposition but may be prompted by environmental factors (Session ED35).

Immunotherapy

Ralph R. Weichselbaum, MD, on Radiotherapy and Immunotherapy in Oligometastatic Disease

Ralph R. Weichselbaum, MD, of the University of Chicago Cancer Research Center, explores the question of whether radiotherapy is the principal curative treatment with immunotherapy or activates immunotherapy. He also discussed how to improve the interaction of these treatments, perhaps with vaccination, transfer of genetically engineered T cells, or checkpoint inhibitors (Session ED37).

COVID-19

Robert A. Winn, MD, on the Impact of COVID-19 on Cancer Care Among Racial and Ethnic Minorities

Robert A. Winn, MD, of Virginia Commonwealth University and the Massey Cancer Center, discusses the COVID-19 pandemic and how it is exacerbating disparities in cancer care among racial and ethnic minorities and the medically underserved who are disproportionately affected by the coronavirus (Session VSS06).

Advertisement

Advertisement



Advertisement